Sample Business Contracts

Collaboration Agreement [Amendment No. 1] - Tularik Inc. and Sumitomo Pharmaceuticals Co. Ltd.

Sponsored Links

                            BETWEEN TULARIK INC. AND
                       SUMITOMO PHARMACEUTICALS CO., LTD

     THIS AMENDMENT NO. 1 (this "Amendment") to the Collaboration Agreement
dated as of January 31, 1995 (the "Collaboration Agreement") by and between
Tularik Inc., a Delaware corporation with its principal office at Two Corporate
Drive, South San Francisco, California 94080 (herein, together with its
successors and assigns, "Tularik"), and Sumitomo Pharmaceuticals Co., Ltd., a
Japanese corporation with its principal office at 2-8, Doshomachi 2-chome Chuo-
ku, Osaka 541, Japan (herein, "Sumitomo"), is entered into as of March 13, 1997;

                              W I T N E S S E T H:

     WHEREAS, the parties previously entered into the Collaboration Agreement;

     WHEREAS, the parties desire to modify Appendix A of the Collaboration

     WHEREAS, in order to accomplish the foregoing, the parties have agreed to
amend the Collaboration Agreement in part;

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
and agreements expressed herein, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, and intending to be
legally bound, Tularik and Sumitomo agree as follows:

     1.   Appendix A of the Collaboration Agreement is hereby amended to add the
following as number 7:

          "7.  [ * ]

     2.   Capitalized terms used herein but not otherwise defined herein shall
have the respective meanings assigned to such terms in the Collaboration

     3.   Except as expressly modified by this Amendment, all of the terms and
conditions of the Collaboration Agreement shall remain in full force and effect.

     4.   This Amendment may be executed in two or more counterparts, each of
which shall be deemed an original but all of which shall be considered one and
the same instrument.


     IN WITNESS WHEREOF, the parties have executed, or caused their duly
authorized officer or representative to execute, this Amendment as of the day
and year first above written.


     By:    /s/ Terry Rosen
     Name:  Terry Rosen
     Title: Vice President, Research Operation


     By:    /s/ Shigeo Ogino
     Name:  Shigeo Ogino
     Title: Managing Director

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.